Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Triamcinolone Injection for Vitiligo
NCT03365141Unknown
- Sponsor
- The Catholic University of Korea
- Start
- Nov 2017
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of triamcinolone acetonide in Vitiligo (2 arms), sponsored by The Catholic University of Korea. Primary endpoint: Repigmentation rate of the vitiliginous patch at 12 weeks. Status: unknown.
02
Drugs
triamcinolone acetonide
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT03365141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03365141.